RGCC Onconomics is a test useful for designing personalized treatment plans for each patient. The test assesses the efficacy of 110+ plus anti-cancer and also incorporates genetic profiling of 80 Plus cancer-related genes, providing insights into how gene expressions and physiological characteristics manifest the cancer.
RGCC Onconomics assesses the sensitivity of Anti-cancer drugs like cytotoxic agents, epothilones, nucleus spindle stabilizers, topoisomerase inhibitors, monoclonal antibodies, small molecular weight molecules, and resistance factors. The epigenetic analysis to determine if genes linked to cancer are over-expressed or downregulated, this information helps to optimize the timing and rotation of treatment regimens to manage cancer cell resistance.
CTC Count: It will act as a prognostic factor by measuring the volume of the cancer cells in your bloodstream which can guide treatment choices toward achieving better results.
Chemosensitivity of anti-cancer drugs: In the one-size-fits-all approach, a uniform method is applied, which might or might not have a significant efficacy. RGCC Onconomics provides information on the most effective anti-drugs against your cancer cells, thus minimizing unnecessary exposure to toxicity.
Epigenetic analysis: Each patient’s gene expression is unique to them, like a fingerprint specific to them. The genetic expressions of your cancer cells can reveal how quickly your cancer cells adapt to become resistant to treatment. Knowing this information can guide how your treatment protocols are set up.
The Onconomics test employs a dual approach, combining molecular and cellular methods to assess the effectiveness of 90+ chemotherapeutic agents and targeted therapies on your cancer cells.
The test applies to all types of cancer and not just limited to the following.
The first step towards personalized cancer care is scheduling an appointment with us.
Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.
We guide you through the process of selecting the most effective tests for your specific cancer.
We deliver precise results that guide treatment decisions and enhance outcomes.
Now, the Circulating Tumour Cells (CTCs) and these Circulating Tumour Cells are grown in the lab and tested against anti-cancer drugs for efficacy (Similar to urine culture for urinary tract infection). Research Genetic Cancer Center (RGCC) in Greece conducts this test. Just by taking a 10ml blood sample, the most effective anti-cancer medicine can be given to patients. In the future, there will not be Breast Oncologists, Musculoskeletal Oncologists, or Head and Neck Oncologists. Only Gene-based Cancer Treatment. The future of oncology is tailor-made Gene-Based Cancer treatment.
Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.
The RGCC Onconomics test is advised for patients who are planning or currently undergoing chemotherapy, especially for those who haven’t shown improvement with initial or subsequent treatments. It’s suitable for those experiencing regular relapse/recurrence, newly diagnosed individuals, cases where the disease is rapidly advancing, or refractory cases with systemic disease.
Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.
Absolutely, tests can be performed while undergoing treatment to assess the effectiveness of the treatment against cancer.
Your blood sample undergoes processing in cutting-edge laboratories by scientists and technicians to deliver insights into your cancer cells.
Yes, all RGCC tests utilize blood samples. However, certain cancers, like glioblastoma and brain tumors, may require additional samples such as CSF or tissue. Otherwise, a peripheral blood sample alone is enough.
Yes, tests like aCGH can pinpoint the origin of an unknown primary tumor by analyzing genetic abnormalities present in tumor cells.
RGCC Metastat is an effective test for identifying secondary tumors development and its potential location. It helps detect secondary tumors through analyzing Circulating Tumor Cells (CTCs) in the bloodstream. The test provides valuable insights into disease progression and metastasis.
Tests personalize treatment regimens by providing crucial information on drugs and therapies tailored to effectively target cancer cells.
Circulating Tumor Cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream. Cancer Stem Cells (CSCs) are a subpopulation of CTCs and both serve as biomarkers for cancer.
Tests like ChemoSNiP and CAMBISeq provide information on the body’s response to the drugs and sensitivity to immunotherapy.
Seeking comprehensive insights into your cancer journey? RGCC Onconomics test provides comprehensive guidance to navigate your battle against cancer. Gain clarity and direction in your treatment path with personalized insights tailored to your unique needs.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
Copyright 2024 © All Right Reserved.
Designed by Bee High Media